Supplementary Figure 1: Trajectories of anti-SARS-CoV-2 Spike protein (anti-S) IgG titres in individual patients following first and second doses of vaccine, stratified by disease subtype.

Figure legend: All figures are presented with a Log10 scale on the y-axis.
*lower limit of assay. **upper limit of assay. HR-MDS High Risk MDS
S1A: Line graph seroconversion rates in patients with no previous SARS-CoV-2 infection, after one and two doses of vaccine (Paired pre dose, post first dose and second dose) in all patients; in patients with AML or HR-MDS (S1B) and in patients with ALL (S1C)
S1D: Seroconversion rates in all patients with previous SARS-CoV-2 infection, after one and two doses of vaccine (Paired pre dose, post first dose and second dose); displayed as a line graph (S1E)
Supplementary Figure 2: Serological responses in patients with Acute leukaemia stratified by therapy

Figure legend: All figures are presented with a log10 scale on the y-axis.
*lower limit of assay, **upper limit of assay, HR-MDS High Risk MDS
S2A: Serological response following two doses of vaccine in AML/HR-MDS treated with venetoclax-based regimens and no evidence of previous SARS-CoV-2 infection
S2B: Serological response following two doses of vaccine in patients treated with Rituimab and non-Rituimab containing regimes:
Median 342 U/mL (IQR 1.69-1541) vs Median 7.5U/mL (IQR 2.6-751.5) p=0.83
S2C: Serological response following two doses of vaccine in patients treated with Rituimab and non-rituximab containing regimes
(Baseline COVID –ve only): Median 2.980 (IQR 0.4-342) vs Median 6.280 U/mL (IQR 3.7-239.7) p=0.6